Products
*Any information on this list of our products available in Japan is not intended to promote or advertise any of the products.
As of October 2024
| Brand Name | Launch | Indications | Licensor | |
|---|---|---|---|---|
| 1 | NOBELZIN® (for Wilson's disease (copper absorption inhibitor)) |
Apr-08 | Wilson’s disease | Teva |
| 2 | LUNABELL® LD (for dysmenorrhea) |
Jul-08 | dysmenorrhea | Janssen |
| 3 | NOBELBAR® (anticonvulsant) |
Dec-08 | neonatal seizures, status epilepticus |
In-house/ Kagawa Univ |
| 4 | Fostoin® (anticonvulsant) |
Jan-12 | status epilepticus, prevention of postoperative seizures, etc. |
Pfizer |
| 5 | INDACIN® (for patent ductus arteriosus in prematurity) |
Jan-13 | patent ductus arteriosus of prematurity | Lundbeck |
| 6 | COSMEGEN® (antitumor antibiotic) |
Jan-13 | Wilms’ tumor, chorionepitelioma, pediatric solid malignant tumor, etc. |
Lundbeck |
| 7 | LUNABELL® ULD (for dysmenorrhea) |
Sep-13 | dysmenorrhea | Janssen |
| 8 | Unitalc® (for pleurodesis) |
Dec-13 | prevention of recurrent malignant pleural effusion | Novatech/ Nagoya Medical Center |
| 9 | Respia® (for apnea of prematurity) |
Dec-14 | apnea of prematurity | Nippon Boehringer (co-development) |
| 10 | RAPALIMUS® (mTOR inhibitor) |
Dec-14 | lymphangioleiomyomatosis | Pfizer/ Niigata Univ |
| 11 | ZANOSAR® (antineoplastic) |
Feb-15 | gastroenteropancreatic neuroendocrine tumor | ESTEVE (former Keocyt) |
| 12 | NOBELZIN® Tablets (hypozincemia) |
Mar-17 | hypozincemia (new indication) | In-house |
| 13 | RAPALIMUS® Gel (for tuberous sclerosis-associated skin lesions (mTOR inhibitor)) |
Jun-18 | tuberous sclerosis-associated skin lesions | Osaka Univ/ In-house |
| 14 | TITANBRIDGE® (thyroid cartilage fixation device) |
Jul-18 | adductor spasmodic dysphonia | TRI (Translational Research Center for Medical Innovation)/ Kumamoto Univ |
| 15 | JEMINA® (for dysmenorrhea) |
Oct-18 | dysmenorrhea | In-house |
| 16 | RETYMPA® (for tympanic membrane perforation) |
Dec-19 | tympanic perforation | TRI/ Kaken |
| 17 | Melatobel® (melatonin receptor agonist for sleep onset improvement) |
Jun-20 | Sleep-onset difficulty associated with neurodevelopmental disorder in children | In-house |
| 18 | RAPALIMUS® (mTOR inhibitor) |
Sep-21 | refractory lymphatic disease [lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham's disease, lymphangiectasia] (new indication) |
Gifu Univ |
| 19 | Unitalc® (for pleurodesis) |
Mar-22 | Inoperable Secondary Intractable Pneumothorax (new indication) |
Nagoya Medical Center |
| 20 | LUNABELL®LD/ULD (for dysmenorrhea) |
Mar-22 | adjustment for Initiation of controlled ovarian stimulation in assisted reproductive technology (new indication) |
In-house |
| 21 | JEMINA® (for dysmenorrhea) |
Mar-22 | adjustment for Initiation of controlled ovarian stimulation in assisted reproductive technology (new indication) |
In-house |
| 22 | NOBELZIN® Granules | Feb-23 | Wilson's disease, hypozincemia | National Center for Child Health and Development All rights reserved. |
| 23 | RAPALIMUS® | Jan-24 | Lymphangioleiomyomatosis The following intractable vascular tumors and intractable vascular malformations: - Lymphatic malformation, - Generalized lymphatic anomaly, - Gorham-Stout disease, - Lymphangiectasia - Hemangioendothelioma, tufted angioma - Venous malformation, blue rubber bleb nevus syndrome - Complex-combined vascular malformation, Klippel-Trenaunay-Weber syndrome |
Gifu Univ |
| 24 | RAPALIMUS® Granules 0.2% | Jul-24 | The following intractable vascular tumors and intractable vascular malformations: - Lymphatic malformation, - Generalized lymphatic anomaly, - Gorham-Stout disease, - Lymphangiectasia - Hemangioendothelioma, tufted angioma - Venous malformation, blue rubber bleb nevus syndrome - Complex-combined vascular malformation, Klippel-Trenaunay-Weber syndrome |
Gifu Univ |
| 25 | Sargmalin® for inhalation 250 µg | Jul-24 | Autoimmune Pulmonary Alveolar Proteinosis | Partner Therapeutics/ Niigata Univ |
| 26 | Zintus® Tablets 50 mg | Aug-24 | Hypozincemia | In-house |
- Research and Development